Document is current
Any future updates will be listed below
-
Authors
Thadhani, Ravi https://orcid.org/0000-0001-8315-9938
Hiemstra, Thomas F. https://orcid.org/0000-0002-2115-8689
Vatish, Manu https://orcid.org/0000-0002-6012-2574
Stepan, Holger
Cerdeira, Ana Sofia https://orcid.org/0000-0002-7643-3537
Brockelsby, Jeremy
James, Tim https://orcid.org/0000-0002-5382-9838
Lia, Massimiliano https://orcid.org/0000-0001-8285-3792
Cornelis, Alissa
Krause, Elena
Spath, Martin R. https://orcid.org/0000-0002-1624-0055
Grüttner, Berthold
Todorova, Polina https://orcid.org/0000-0002-4728-224X
Hagmann, Henning
Yeung, Kristen R.
Xu, Bei
Heffernan, Scott
Pears, Suzanne
Waugh, Richard
Thompson, John https://orcid.org/0000-0002-2816-2496
Iliopoulos, Jim
Sunderland, Neroli
Killingsworth, Murray https://orcid.org/0000-0002-6125-1183
Makris, Angela
Hennessy, Annemarie https://orcid.org/0000-0002-5975-2843
Lo, Agnes
Tan, Adelene Y.
Kussie, Paul
Chang, Yuchiao
Hanssens, Linda
Miltenyi, Stefan
Benzing, Thomas https://orcid.org/0000-0003-0512-1066
Karumanchi, S. Ananth https://orcid.org/0000-0002-2281-6831
-
Funding
Funding for this research was provided by:
Miltenyi Biomedicine Aggamin Pharmaceuticals
- License Information
-
More Information
Article History
Received: 5 September 2025
Accepted: 10 March 2026
First Online: 27 April 2026
Competing interests
: R.T. and S.A.K. are co-inventors on multiple biomarker patents related to preeclampsia that have been out-licensed to several companies (Thermo Fisher Scientific, Beckman Coulter, Siemens and Roche) and report financial interest in Aggamin Pharmaceuticals and serving as a consultant to Comanche Biopharma. R.T. and S.A.K. are named as co-inventors on a provisional patent held by Cedars-Sinai Medical Center on a novel lateral-flow diagnostic assay for use in preeclampsia and related conditions. A.H. is an advisor to Comanche Biopharma. A.Y.T. and P.K. are employees of Aggamin Pharmaceuticals. L.H. is an employee of, and S.M. is the founder of, Miltenyi Biomedicine. All other authors disclose no conflicts. These financial interests have been disclosed in accordance with journal policies.
